Huet D, Godbert B, Hermann J, Zordan J-M, Chabot F, Andréjak C
CHRU de Nancy, bâtiment des spécialités médicales Philippe Cantion, rue du Morvan, 54511 Vandoeuvre-les-Nancy cedex, France.
Service de pneumologie, hôpital Robert-Schuman, 57070 Vantoux, France.
Rev Mal Respir. 2017 Mar;34(3):257-261. doi: 10.1016/j.rmr.2016.05.012. Epub 2016 Sep 14.
Pulmonary infection due to Mycobacterium malmoense can be difficult to diagnose. These difficulties can be responsible for a delay in the implementation of optimal treatment. Moreover, the treatment is not standardized.
We report the case of a 56-year-old patient who developed a Mycobacterium malmoense pulmonary infection whose diagnosis was delayed due to initial suspicion of pulmonary Mycobacterium tuberculosis infection. Once the diagnosis was confirmed, the patient was treated empirically with rifampicin, ethambutol, and clarithromycin for 12 months after culture conversion, giving a total of 15 months. The clinical and radiological outcomes were favorable.
This clinical case highlights the difficulties of diagnosing pulmonary atypical mycobacterial infection according to the American Thoracic Society criteria, particularly Mycobacterium malmoense, a non-tuberculous mycobacterium (NTM) quite uncommon in France. Currently, there are new diagnostic techniques such as GenoType Mycobacteria Direct. The second issue is the poorly standardized treatment of this NTM and many others, that are based on the recommendations of the British Thoracic Society. A national register has been set up by the MycoMed network, based essentially on the work of microbiologists but this register is unfortunately not exhaustive.
A more systematic reporting strategy could allow cohort studies and therefore provide us with data on the most efficient drugs in the treatment of the rarest NTM infections.
马尔默分枝杆菌引起的肺部感染可能难以诊断。这些困难可能导致最佳治疗的实施延迟。此外,治疗并不规范。
我们报告一例56岁患者,其发生了马尔默分枝杆菌肺部感染,由于最初怀疑为肺结核分枝杆菌肺部感染,诊断有所延迟。确诊后,患者在培养结果转阴后接受利福平、乙胺丁醇和克拉霉素经验性治疗12个月,总共治疗15个月。临床和影像学结果良好。
该临床病例凸显了根据美国胸科学会标准诊断肺部非典型分枝杆菌感染的困难,尤其是马尔默分枝杆菌,这是一种在法国相当罕见的非结核分枝杆菌(NTM)。目前有新的诊断技术,如GenoType分枝杆菌直接检测法。第二个问题是这种NTM以及许多其他NTM的治疗规范不足,其治疗是基于英国胸科学会的建议。MycoMed网络建立了一个国家登记册,主要基于微生物学家的工作,但遗憾的是,这个登记册并不详尽。
更系统的报告策略可以开展队列研究,从而为我们提供有关治疗最罕见NTM感染的最有效药物的数据。